Who Paid My Doc
Divya Vats
Clinical Biochemical Genetics Los Angeles, CA Medical Doctor
NPI 1154515963 CMS profile 367763
4650 W Sunset Blvd, Mail Stop # 90, Los Angeles, CA 90027
General payments
$3,579
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$230,269
Through program year 2024, Divya Vats of Los Angeles, CA is reported in the CMS Open Payments database as having received $3,579 across 11 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $230,269 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $1,300 | 2 | |
| 2023 | General | $125 | 1 | |
| 2022 | General | $125 | 1 | |
| 2021 | General | $125 | 1 | |
| 2020 | General | $1,562 | 3 | |
| 2019 | General | $342 | 3 |
Beside peers
- Divya Vats
- Clinical Biochemical Genetics median
- Middle half of Clinical Biochemical Genetics
- National median
In program year 2025, general payments to Divya Vats were reported at $0. Among 23 Clinical Biochemical Genetics profiles paid that year, the median was $237 and the middle half received between $88 and $2,648.
Show as a table
| Year | Divya Vats | Clinical Biochemical Genetics median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $342 | $132 | $20–$1,451 | $163 |
| 2020 | $1,562 | — | — | $114 |
| 2021 | $125 | — | — | $132 |
| 2022 | $125 | $157 | $94–$2,848 | $149 |
| 2023 | $125 | $242 | $71–$1,706 | $160 |
| 2024 | $1,300 | — | — | $164 |
| 2025 | $0 | $237 | $88–$2,648 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
155
Drug cost
$2,743,395
Branded share of claims
72.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Galafold Migalastat Hcl | Brand | 53 | $1,604,527 | |
| Cerdelga Eliglustat Tartrate | Brand | 45 | $959,427 | |
| Palynziq Pegvaliase-Pqpz | Brand | 14 | $177,464 | |
| Albuterol Sulfate | Generic | 32 | $1,822 | |
| Tizanidine Hcl | Generic | 11 | $157 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Records
11 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Biochemical Genetics in California
Related records
Clinical Biochemical Genetics in California
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Biochemical Genetics
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.